Treatment of Schizophrenia
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Antipsychotic medication remains a mainstay of treatment in both acute and chronic schizophrenia. Emphasis in recent years has focused on maximizing benefits and minimizing risks of medication by attempting to establish minimum effective dosage requirements for all phases of treatment and to provide alternative strategies for individuals who fail to benefit from antipsychotic drug treatment. At present all approaches to the treatment-refractory patient remain experimental, and further research in this area is of critical importance. Definite advances have been made in exploring the impact of psychological and psychosocial treatments administered in conjunction with various antipsychotic drug strategies. More sophisticated and comprehensive assessment measures have been applied in long-term treatment trials, enabling us to be more specific about treatment goals and treatment evaluation. Although no major "breakthrough" has occurred in the treatment of schizophrenia, incremental advances which can reduce rates of relapse and rehospitalization, improve the quality of adaptation, and reduce the risk of significant adverse effects are of enormous importance to affected individuals, their families, and society at large.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Comparative Studies of Psychotherapies: Is It True That "Everyone Has Won and All Must Have Prizes"?
Luborsky, L. (1975) · Archives of General Psychiatry · doi:10.1001/archpsyc.1975.01760260059004 · Cited by 1,485
DISEASES OF THE NERVOUS SYSTEM
JELLIFFE, S. E., & WHITE, W. A. (1918) · The American Journal of the Medical Sciences · doi:10.1097/00000441-191803000-00015 · Cited by 1,277
Psychopharmacology : a generation of progress
Lipton, M. A., DiMascio, A., & Killam, K. F. (1978) · DigitalGeorgetown (Georgetown University Library) · Cited by 1,212
Hogarty, G. E. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800070019003 · Cited by 917
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.6.727 · Cited by 854
A Survey of Drug-Induced Extrapyramidal Reactions
Ayd, F. J. (1961) · JAMA · doi:10.1001/jama.1961.03040120016004 · Cited by 753
Tardive Dyskinesia: Prevalence and Risk Factors, 1959 to 1979
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040069010 · Cited by 656
Self-citationDrug and Sociotherapy in the Aftercare of Schizophrenic Patients: II. Two-Year Relapse Rates
Hogarty, G. E. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760170005001 · Cited by 573
Why Do Schizophrenic Patients Refuse to Take Their Drugs?
Van Putten, T. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760130049008 · Cited by 572
Drug and Family Therapy in the Aftercare of Acute Schizophrenics
Goldstein, M. J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770340019001 · Cited by 517
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., MacMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Catamnestic Long-term Study on the Course of Life and Aging of Schizophrenics
Ciompi, L., & Clemens, S. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.4.606 · Cited by 464
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.7.801 · Cited by 455
Longitudinal Studies of Schizophrenic Patients
Huber, G., Gross, G., Schuttler, R., Linz, M., & Clemens, S. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.4.592 · Cited by 439
Psychopharmacology: A Generation of Progress
Abrams, A. A. (1978) · Psychosomatic Medicine · doi:10.1097/00006842-197810000-00010 · Cited by 416
Overview: maintenance therapy in psychiatry: I. Schizophrenia
(1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.12.1237 · Cited by 410
The schizophrenic disorders: Long-term patient and family studies
BLEULER, M. (1978) · Medical Entomology and Zoology · Cited by 388
Three Lectures on Schizophrenia: The Natural History of Schizophrenia in the Long Term
Ciompi, L. (1980) · British Journal of Psychiatry · doi:10.1192/bjp.136.5.413 · Cited by 370
Hogarty, G. E. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780120013001 · Cited by 365
Trial of Maintenance Therapy in Schizophrenia
Leff, J. P., & Wing, J. K. (1971) · BMJ · doi:10.1136/bmj.3.5775.599 · Cited by 338
Weinberger, D. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140013001 · Cited by 323
Provocation of Schizophrenic Symptoms by Intravenous Administration of Methylphenidate
Janowsky, D. S. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750320023004 · Cited by 310
Effects of Psychotherapy in Schizophrenia: II. Comparative Outcome of Two Forms of Treatment
Gunderson, J. G., Frank, A. F., Katz, H. M., Vannicelli, M. L., Frosch, J. P., & Knapp, P. H. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.4.564 · Cited by 304
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301 · cited 1×
“Chouinard and Jones (1980) have proposed a concept of "supersensitivity psychosis" which implies that following drug treatment, the risk of relapse is increased by an increase in sensitivity of dopamine receptors in relevant brain areas.”
BackgroundImportant Issues in the Drug Treatment of Schizophrenia
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 284
Kane, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070083010 · Cited by 273
Self-citationUnderstanding and Treating Tardive Dyskinesia
Jeste, D. V., Wyatt, R. J., & TUPIN, J. P. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198306000-00037 · Cited by 260
Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C., & Wing, J. K. (1973) · BMJ · doi:10.1136/bmj.1.5854.633 · Cited by 259
Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome
Marder, S. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180028005 · Cited by 245
Social skills training for patients with schizophrenia: A controlled clinical trial
Wallace, C. J., & Liberman, R. P. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90081-2 · Cited by 237
Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290010048009 · Cited by 222
Self-citationPrediction of Relapse in Schizophrenic Outpatients Treated by Drug and Sociotherapy
Goldberg, S. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770140061008 · Cited by 218
Acute dystonia induced by neuroleptic drugs
Rupniak, N. M. J., Jenner, P., & Marsden, C. D. (1986) · Psychopharmacology · doi:10.1007/bf00178501 · Cited by 218
Integrating incidence and prevalence of tardive dyskinesia.
Kane, J. M., Woerner, M. G., Borenstein, M., Wegner, J. T., & Lieberman, J. A. (1986) · PubMed · Cited by 207
Self-citationMethylphenidate, Dextroamphetamine, and Levamfetamine: Effects on Schizophrenic Symptoms
Janowsky, D. S. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770030024003 · Cited by 205
Falloon, I., Watt, D. C., & Shepherd, M. (1978) · Psychological Medicine · doi:10.1017/s0033291700006632 · Cited by 196
Costs and Benefits of Two Doses of Fluphenazine
Marder, S. R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220015002 · Cited by 182
Effects of Psychotherapy in Schizophrenia: I. Design and Implementation of a Controlled Study
Stanton, A. H., Gunderson, J. G., Knapp, P. H., Frank, A. F., Vannicelli, M. L., Schnitzer, R., & Rosenthal, R. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.4.520 · Cited by 180
Prevention of Relapse in Schizophrenia: An Evaluation of Fluphenazine Decanoate
Schooler, N. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140018002 · Cited by 177
Rifkin, A. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770130045004 · Cited by 175
Schizophrenia—A Follow-up Study of Results of Treatment: II. Hospital Stay Over Two to Five Years
May, P. R. A. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770040047009 · Cited by 175
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.7.918 · Cited by 168
Taylor, P. J., & Fleminger, J. J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92653-7 · Cited by 148
Receptor-Binding Profiles of Neuroleptics
Hyttel, J., Larsen, J. ‐., Christensen, A. V., & Arnt, J. (1985) · Psychopharmacology series · doi:10.1007/978-3-642-70140-5_2 · Cited by 145
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects
Angrist, B., Rotrosen, J., & Gershon, S. (1980) · Psychopharmacology · doi:10.1007/bf00427592 · Cited by 140
Treatment of schizophrenia : a comparative study of five treatment methods
May, P. R. A. (1968) · Medical Entomology and Zoology · Cited by 137
Rapid Treatment of Acute Psychotic Symptoms With High- and Low-Dose Haloperidol
Neborsky, R. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780270081011 · Cited by 134
An Examination of the Efficacy of Social Skills Training for Chronic Schizophrenic Patients
Bellack, A. S., Turner, S. M., Hersen, M., & Luber, R. F. (1984) · Psychiatric Services · doi:10.1176/ps.35.10.1023 · Cited by 132
Dissimilar dosing with high-potency and low-potency neuroleptics
Baldessarini, R. J., Katz, B., & Cotton, P. G. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.6.748 · Cited by 131
Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
Richelson, E. (1984) · PubMed · Cited by 127
Dyskinesia. Research and treatment.
Casey, D. E. (1985) · PubMed · Cited by 126
"Everyone has won and all must have prizes".
Turk, D. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200006000-00001 · Cited by 124
Drug discontinuation among long term, successfully maintained schizophrenic outpatients.
Ge, H., Ulrich, R. F., Mussare, F., & Aristigueta, N. (1976) · PubMed · Cited by 118
Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods.
Langner, H. P. (1969) · Archives of General Psychiatry · doi:10.1001/archpsyc.1969.01740160108017 · Cited by 114
Wistedt, B. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00761.x · Cited by 113
Incidence of tardive dyskinesia: five-year data from a prospective study.
Kane, J. M., Woerner, M. G., Weinhold, P., Wegner, J. T., Kinon, B. J., & Borenstein, M. (1984) · PubMed · Cited by 111
Self-citationAre Prophylactic Antiparkinson Drugs Necessary?
Rifkin, A. E. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280093010 · Cited by 111
Discontinuation or reduction of chemotherapy in chronic schizophrenics
Caffey, E. M., Diamond, L. S., Frank, T. V., Grasberger, J. C., Herman, L., Klett, C. J., & Rothstein, C. (1964) · Journal of Chronic Diseases · doi:10.1016/0021-9681(64)90075-x · Cited by 110
Psychosocial Treatment: Individual, Group, Family, and Community Support Approaches
Mosher, L. R., & Keith, S. J. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.10 · Cited by 107
Wode‐Helgodt, B., Borg, S., FYRÖ, B., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb06929.x · Cited by 99
Phenothiazines in Prevention of Psychiatric Hospitalization
Engelhardt, D. M., Rosen, B., Freedman, N., & Margolis, R. (1967) · Archives of General Psychiatry · doi:10.1001/archpsyc.1967.01730190100013 · Cited by 93
Relationship of serum haloperidol levels to clinical response in schizophrenic patients
Magliozzi, J. R., Hollister, L. E., Arnold, K., & Earle, G. M. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.3.365 · Cited by 93
Fluphenazine pharmacokinetics and therapeutic response
Dysken, M. W., Javaid, J. I., Chang, S. S., Schaffer, C. B., Shahid, A., & Davis, J. M. (1981) · Psychopharmacology · doi:10.1007/bf00422403 · Cited by 91
Lithium Treatment in Schizophrenia and Schizo-Affective Disorders
Delva, N. J., & Letemendia, F. J. J. (1982) · The British Journal of Psychiatry · doi:10.1192/bjp.141.4.387 · Cited by 90
Leicester ECT Trial: Results in Schizophrenia
Brandon, S., Cowley, P., Mcdonald, C., Neville, P., Palmer, R., & Wellstood-Eason, S. (1985) · British Journal of Psychiatry · doi:10.1192/bjp.146.2.177 · Cited by 86
Bj�rndal, N., Bjerre, M. T., Gerlach, J., Kristjansen, P., Magelund, G., Oestrich, I. H., & W�hrens, J. (1980) · Psychopharmacology · doi:10.1007/bf00427590 · Cited by 85
Methylphenidate challenge as a predictor of relapse in schizophrenia
Lieberman, J. A., Kane, J. M., Gadaleta, D. J., Brenner, R., LESSER, M., & Kinon, B. J. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.5.633 · Cited by 84
Self-citationSchizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?
Cheung, H. K. (1981) · British Journal of Psychiatry · doi:10.1192/bjp.138.6.490 · Cited by 82
Clinical response and plasma haloperidol levels in schizophrenia
Mavroidis, M. L., Kanter, D. R., Hirschowitz, J., & Garver, D. L. (1983) · Psychopharmacology · doi:10.1007/bf00427577 · Cited by 82
Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Sandler, A. P., THOMPSON, J. E., & Putney, D. (1984) · PubMed · Cited by 80
Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics
Crawford, R. S., & Forrest, A. D. (1974) · The British Journal of Psychiatry · doi:10.1192/bjp.124.4.385 · Cited by 73
Further Observations on the Duration of Depot Neuroleptic Maintenance Therapy in Schizophrenia
Johnson, D. A. W. (1979) · The British Journal of Psychiatry · doi:10.1192/bjp.135.6.524 · Cited by 66
The action of neuroleptic drugs
Haase, H. J., & Janssen, P. A. J. (1985) · Elsevier eBooks · Cited by 57
Dencker, S. J., Lepp, M., & Malm, U. (1980) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1980.tb07084.x · Cited by 57
Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
Ericksen, S. E., Sw, H., & Chang, S. (1978) · PubMed · Cited by 57
Amphetamine response and relapse risk after depot neuroleptic discontinuation
ANGRIST, B. M., Peselow, E. D., Rubinstein, M. E., Wolkin, A., & Rotrosen, J. (1985) · Psychopharmacology · doi:10.1007/bf00428187 · Cited by 55
Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics
Quitkin, F. M. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310095007 · Cited by 55
Hj, H. (1961) · PubMed · Cited by 55
Life Skills Training for Chronic Schizophrenics
BROWN, M. A., & MUNFORD, A. M. (1983) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198308000-00003 · Cited by 52
Compliance in the long-term treatment of schizophrenia.
Kane, J. M., & Borenstein, M. (1985) · PubMed · Cited by 52
Self-citationIntermittent Pimozide versus Fluphenazine Decanoate as Maintenance Therapy in Chronic Schizophrenia
McCreadie, R. G., Dingwall, J. M., Wiles, D. H., et al. (1980) · The British Journal of Psychiatry · doi:10.1192/bjp.137.6.510 · Cited by 50
Drug Maintenance Strategies in Schizophrenia
SLAWSKY, R. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.101-a · Cited by 43
Plasma Levels and Clinical Effects of Thioridazine and Thiothixene
Bergling, R., Mjörndal, T., Oreland, L., RAPP, W., & Wold, S. (1975) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1975.tb02354.x · Cited by 36
The Influence of Group Therapy on Schizophrenia
Malm, U. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb00288.x · Cited by 34
Kelly, H. B., Freeman, H. L., Banning, B., & Schiff, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000468286 · Cited by 30
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Neborsky, R. J., Ds, J., Perel, J. M., et al. (1984) · PubMed · Cited by 29
Smith, R. C., Baumgartner, R., Shvartsburd, A., Ravichandran, G., Vroulis, G., & Mauldin, M. (1985) · Psychopharmacology · doi:10.1007/bf00429663 · Cited by 27
Goldhamer, P. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780320122016 · Cited by 20
Psychosocial Treatment of Schizophrenia, or Psychosocial Help for People With Schizophrenia?
Klein, D. F. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.122 · Cited by 19
Therapeutic blood levels of fluphenazine: plasma or RBC determinations?
Mavroidis, M. L., Kanter, D. R., Hirschowitz, J., & Dl, G. (1984) · PubMed · Cited by 18
A Step Forward in Research on Psychotherapy of Schizophrenia
May, P. R. A. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.4.604 · Cited by 17
Mackay, A. V. P. (1982) · Elsevier eBooks · doi:10.1016/b978-0-407-00212-8.50009-5 · Cited by 13
Cited by
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.
Spohn, H. E., & Strauss, M. E. (1989) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.98.4.367 · Cited by 381
Metadata
- Authors
- Kane, J. M.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1987-01-01
- Volume
- 13
- Issue
- 1
- Pages
- 133-156
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2150727954
- Cited by
- 323
- References
- 93
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.